Revolutionizing Pain Management in Urgent Care Centers
United Pain Urgent Care is Pioneering Non-Opioid Solutions for Acute Pain RENO, NV / ACCESSWIRE / April 17, 2023 /...
Healthcare
CharmHealth Unveils 2024 Innovation Challenge to Bring Creative Solutions to the Fingertips of Healthcare Providers
Call for Proposals Now Open to Digital Health Startups to Compete on the CharmHealth EcosystemPLEASANTON, Calif.--(BUSINESS WIRE)--#AI--CharmHealth, a leader in...
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will...
Suki Assistant Receives 93.2 Overall Performance Score in 2024 KLAS Spotlight Report
Respondents indicate that the company’s ambient AI solution is highly effective in decreasing burnout, improving same-day closures, and driving tangible...
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Study will assess the clinical utility and workflow benefits of physicians using images acquired by the Swoop® Portable MR Imaging®...
Establishment Labs Announces Participation in The Aesthetic Meeting 2024
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
AGFA HealthCare and Konimagem to Ignite Radiology Innovations at JPR 2024 in Brazil
MORTSEL, BELGIUM / ACCESSWIRE / April 17, 2024 / Having celebrated 12 months back in the Brazilian market, imaging IT...
New Study Shows 94% Reduction in COVID-19 Cases in a Residential Healthcare Facility With ActivePure Technology
Technology offers timely and cost-efficient infection prevention solution for long-term care amidst industry-wide labor shortagesDALLAS, TX / ACCESSWIRE / April...
Notice of Annual General Meeting in Senzime ab (PUBL)
UPPSALA, SWEDEN / ACCESSWIRE / April 17, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) The shareholders in Senzime AB (publ) corp. reg. no...
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
TORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Mobile-health Network Solutions Ranked Number 41 in Financial Times Listing of 500 High-growth Asia-Pacific Companies
SINGAPORE, April 17, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR), a leading telehealth solutions provider in Singapore, today...
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to presentSOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke...
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
New patent-protected, central recruitment leverages the Science 37 Metasite™ to accelerate enrollment and dramatically reduce site burdenRESEARCH TRIANGLE PARK, N.C.,...
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing...
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE...
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing...
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between...